Lonza announces CHF10m Singapore biomanufacturing expansion
Switzerland-based life sciences supplier Lonza says it will invest CHF10m (€8m) to expand a Singapore plant that is part of its custom biomanufacturing business.
Lonza wins manufacturing deals with Enobia and Athera
Switzerland-based Lonza has signed two new manufacturing deals with pharmaceutical firms that look set to improve capacity utilisation.
Lonza boosts capacity use but tough regulators add volatility
Lonza is seeing increased capacity utilisation and project pipelines in custom manufacturing but warned more stringent regulatory approval is creating volatility.
Lonza grows H1 profit despite dip in sales
Lonza has posted a 14.4 per cent increase in net profit in the first half of 2010, despite a dip in sales.
Lonza reports stronger demand in Q1 but remains cautious
Lonza has reported stronger demand in the first quarter, but volatility remains in the custom manufacturing sector and it is uncertain if improvements “represent true and full economic recovery”.
Appointments at Lonza, Quanticate, BioClinica, TechTeam and Norwich Pharmaceuticals – People on the move
Outsourcing-Pharma presents its latest round up of movements in the pharma outsourcing sector, including appointments at Lonza, Quanticate, BioClinica, TechTeam and Norwich Pharmaceuticals.
Lonza hit by lower demand last year; cuts capex in 2010
Full-year income at the Lonza was hit by falling demand for life science ingredients and custom manufacturing services and only modest gains for its bioscience unit.
Lonza buys into immunogenicity
Lonza has bolstered its protein design capabilities by acquiring Algonomics, a CRO with technologies which predict immunogenicity to improve development of protein therapeutics and vaccines.
Lonza builds in India in Simbiosys deal; updates on Patheon takeover
Lonza says that to the Indian market was a key motivation for its acquisition of Simbiosys Biowares India preclinical cell and molecular biology assets.
Will Lonza's $460m Patheon offer trigger bidding war?
Canadian contractor Patheon has welcomed the $460m (€321m) takeover offer from Switzerland's Lonza that could, according to some observers, spark a bidding war with rival suitor, US group JLL Patheon Holdings.
LFB picks Lonza for CMO deal
French biopharmaceutical group LFB has contracted Lonza’s biopharmaceuticals division to make trial supplies of its candidated monoclonal anti-RhD antibody.
Lonza inks strategic long-term deal
Medarex has secured the option to use Lonza’s manufacturing services in the development and commercialisation of its therapeutic proteins and antibody drug conjugates.
Altus accuses Lonza of breaching contract
Altus Pharmaceuticals has terminated its contract with Lonza over an alleged breach in the agreement to provide active pharmaceutical ingredients (API) for Trizytek (liprotamase).
Lonza’s GS system wins Elusys anthrax Ab contract
Swiss life sciences solutions firm Lonza has been contracted by US biotechnology group Elusys Therapeutics to produce Anthim, its late stage Ab candidate treatment for anthrax infection.
Emerson wins Singapore bio plant contract
Industrial automation specialist Emerson Process Management has won the contract to help Swiss life sciences group Lonza design its new biopharmaceuticals plant in Singapore.